Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. (EVGN) is a leader in computational biology, leveraging AI and big data to drive innovation in agriculture, health, and industrial applications. This page provides centralized access to official press releases and verified news about the company’s advancements in predictive biology and strategic initiatives.
Investors and industry stakeholders will find timely updates on product developments, research milestones, and strategic collaborations, including those involving subsidiaries Lavie Bio and Biomica. Track announcements related to MicroBoost AI and GeneRator AI platforms, agricultural bio-inoculants, and castor seed innovations for bio-based industries.
Content spans earnings reports, partnership agreements, regulatory updates, and technology breakthroughs. Bookmark this page to stay informed about Evogene’s progress in enhancing crop productivity, therapeutic discoveries, and sustainable industrial solutions through cutting-edge computational methods.
Biomica Ltd., a subsidiary of Evogene Ltd. (Nasdaq: EVGN), has successfully closed a financing round totaling $20 million, aimed at advancing its microbiome-based therapeutics. The funding was primarily led by a $10 million investment from Shanghai Healthcare Capital, which now owns 20% of Biomica's shares. The funds will be allocated to complete the BMC128 phase 1 immuno-oncology study and initiate a phase 2 trial, as well as to scale up GMP production of BMC333 for an upcoming phase 1 clinical trial focused on inflammatory bowel disease (IBD). Biomica is dedicated to developing innovative therapeutics utilizing its MicroBoost AI technology, emphasizing treatments for antibiotic-resistant bacteria and gastrointestinal disorders.
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
